EpiCept pain therapy patch fails Phase III trial

EpiCept's LidoPAIN, an analgesic pain therapy patch, failed a Phase III trial in Europe. According to researchers, LidoPAIN SP "did not achieve a statistically significant effect relative to placebo with respect to the primary endpoint of self-assessed pain intensity between 4 and 24 hours. In addition, a statistically significant effect was not achieved in the trial's co-primary endpoint of patient use of "rescue" medications, i.e. systemically-delivered analgesics used to alleviate pain." EpiCept secured a $10 million loan a week ago. Endo Pharmaceuticals has signed on as a commercialization partner for LidoPAIN.

- see the release on LidoPAIN

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.